非布司他治疗慢性肾脏病伴高尿酸血症的安全性分析

The safety of febuxostat in the treatment of chronic kidney disease with hyperuricemia

目的分析非布司他治疗慢性肾脏病伴高尿酸血症的临床效果以及安全性分析。方法选取2017年2月至2018年2月期间本院慢性肾脏病伴高尿酸血症患者100例(实施信封随机分组模式)。分别给予别嘌醇片、非布司他进行治疗,对比两组临床疗效、相关指标情况、不良反应发生情况。结果观察组显效例数有40例,血尿酸为(384.57±59.68)μmol/L、血肌酐为(75.54±6.66)μmol/L、尿素氮为(5.14±1.12)mmol/L、不良反应发生例数有3例,数据与对照组数据之间进行比较,差异有统计学意义(P<0.05)。结论非布司他治疗慢性肾脏病伴高尿酸血症效果较佳,同时治疗过程中不良反应发生例数较低,安全有效,可推广。

Objective To analyze the clinical efficacy and safety of febuxostat in the treatment of chronic kidney disease with hyperuricemia.Methods From February 19,2017 to February 19,2018,we selected 100 patients with chronic kidney disease and hyperuricemia in our hospital(enforcement of the envelope randomization model).The allopurinol tablets and febuxostat were administered respectively to compare the clinical efficacy,related indicators,and adverse reactions between the two groups.Results There were 40 cases in the observation group,uric acid was(384.57±59.68)μmol/L,serum creatinine was(75.54±6.66)μmol/L,and urea nitrogen was(5.14±1.12)mmol/L.Adverse reactions occurred.The number of cases was 3,and the difference between the data and the control group data was significant(P<0.05).Conclusion Fenofibrate is effective in treating chronic kidney disease with hyperuricemia.At the same time,the number of adverse reactions in the course of treatment is low,safe and effective,and can be popularized.